Table 4.
Multivariable survival analysis including neutrophil-to-lymphocyte ratio (NLR) for the 603 patients under study.
| Overall Survival | Cancer-related Survival | |||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Age (years) | <0.001 | 0.017 | ||
| ≤68.9 years | — | — | ||
| >68.9 years | 2.98 (2.07–4.29) | 1.69 (1.09–2.61) | ||
| Gender | 0.10 | 0.08 | ||
| Female | — | — | ||
| Male | 1.33 (0.95–1.87) | 1.50 (0.96–2.36) | ||
| Histological Type | 0.46 | 0.10 | ||
| Adenocarcinoma | — | — | ||
| Mucinous | 0.85 (0.56–1.30) | 0.61 (0.33–1.01) | ||
| TNM Stage | <0.001 | <0.001 | ||
| Stage I | — | — | ||
| Stage II | 1.59 (0.90–2.82) | 2.73 (0.92–8.13) | ||
| Stage III | 2.92 (1.66–5.13) | 9.65 (3.43–27.14) | ||
| Stage IV | 6.49 (3.45–12.21) | 29.78 (10.22–86.75) | ||
| Neutrophil-to-lymphocyte ratio | 0.003 | 0.40 | ||
| L-NLR | — | — | ||
| H-NLR | 1.15 (0.86–1.54) | 1.22 (0.77–1.93) | ||
aValues in parentheses are 95% confidence intervals. Hazard ratio and p values were derived from Cox regression analysis, controlling for all other variables.